AsiDNA™ Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance

Onxeo is pleased to report the availability in Neoplasia of a publication highlighting two unique properties of AsiDNA™, cumulative efficacy and absence of resistant clones post-treatments:

https://www.sciencedirect.com/science/article/pii/S1476558619302131

Publication in PDF